Rezulin return unlikely
Pfizer has no plans to reintroduce the Type 2 diabetes therapy Rezulin, the company said. At the recent Pharmaceutical Research & Manufacturers of America annual meeting, Agency for Healthcare Research & Quality Director Carolyn Clancy commented during a panel discussion on data she recently saw suggesting that Rezulin had no greater risk of liver toxicity than the background rate. Clancy speculated that the product could be a candidate for reintroduction, based on that data. Rezulin (troglitazone) was withdrawn by Warner-Lambert in 2000 after FDA concluded that two competing agents, Actos and Avandia, have a better safety profile...
You may also be interested in...
AstraZeneca's CEO and other leaders from COVID-19 vaccine companies will face some tough questions in Brussels, but the European Commission wants to put differences behind it and solve the vaccine supply problem as soon as possible.
Abingdon Health has announced that a study run in conjunction with the UK Rapid Test Consortium has demonstrated that its AbC-19 test could be an effective tool for testing vaccine efficacy.
NGO says the Expert Panel for Cosmetic Ingredient Safety’s conclusion on methylisothiazolinone in 2020 was among decisions “not in the interest of public health.” However, other assessments highlighted by the group suggest that the Cosmetic Ingredient Review is working as an open forum for public input and discussion.